# Nouscom

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nouscom

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.nouscom.com
- Total disclosed funding: $281M
- Latest round: Series D (Oct 19, 2026)
- Investors on record: 27

## About

Based in Basel, Switzerland, and co-founded by Riccardo Cortese in 2015, Nouscom AG operates as a clinical-stage immuno-oncology company. In March 2024, Nouscom AG raised EUR 7 million in an extended series C funding from Angelini Ventures. The investment brings the total Series C funding to EUR 75.8 million. As of 2024, the company is led by its CEO, Marina Udier.

Nouscom develops off-the-shelf and personalized cancer immunotherapies. The firm’s pipeline product line includes NOUS-209, which is an immunotherapy designed to treat various solid tumors and prevent cancer in individuals with Lynch syndrome; and NOUS-PEV, a personalized immunotherapy aimed at treating cancers.

The company plans to use the funds raised in March 2024 to enhance and broaden its clinical pipeline to achieve multiple clinical value catalysts.

## Funding rounds

- Series D, Oct 19, 2026, $135M — M Ventures, Revelation Partners, Angelini Industries, Angelini Investments, Aurea, Banca Europea per gli Investimenti, BEI, Bpifrance, CDP Venture Capital, EIB, EQT Life Sciences, European Investment Bank, Indaco Venture Partners, Indaco Venture Partners sgr, InnoBio2, Intesa Sanpaolo, Neva SGR, Panakès Partners, Versant Ventures, 5AM Ventures, XGEN Ventures, Andera Partners
- Series C, Mar 21, 2024, $7.6M — Angelini Ventures
- Series C, Nov 14, 2023, $73M — Versant Ventures, Andera Partners, EQT Life Sciences, 5AM Ventures, M Ventures, Bpifrance Investissement, Revelation Partners, Panakes Partners, Indaco Venture Partners, XGEN Venture
- Series B, Nov 6, 2017, $49M — Abingworth, Versant Ventures, EQT Life Sciences, 5AM Ventures
- Series A, Jun 1, 2014, $16M — Versant Ventures, EQT Life Sciences

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C, Series D
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B, Series C, Series D
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series B, Series C, Series D
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series C, Series D
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series C, Series D
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series C
- Revelation Partners (https://capitalatlas.ai/funds/revelation-partners) — Series C, Series D
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series C
- Indaco Venture Partners (https://capitalatlas.ai/funds/indaco-venture-partners) — Series C, Series D
- XGEN Venture (https://capitalatlas.ai/funds/xgen-venture) — Series C
- Angelini Ventures (https://capitalatlas.ai/funds/angelini-ventures) — Series C
- Angelini Industries — Series D
- Angelini Investments — Series D
- Aurea — Series D
- Banca Europea per gli Investimenti — Series D
- BEI — Series D
- Bpifrance — Series D
- CDP Venture Capital (https://capitalatlas.ai/funds/cdp-venture-capital) — Series D
- EIB — Series D
- European Investment Bank (https://capitalatlas.ai/funds/european-investment-bank) — Series D
- Indaco Venture Partners sgr — Series D
- InnoBio2 — Series D
- Intesa Sanpaolo — Series D
- Neva SGR — Series D
- Panakès Partners — Series D
- XGEN Ventures — Series D